The flow cytometry-defined light chain cytoplasmic immunoglobulin index and an associated 12-gene expression signature are independent prognostic factors in multiple myeloma

X Papanikolaou1, D Alapat2, A Rosenthal3, C Stein1, J Epstein1, R Owens2, S Yaccoby1, S Johnson1, C Bailey1, C Heuck1, E Tian1, A Joiner2, F van Rhee1, R Khan1, M Zangari1, Y Jethava1, S Waheed1, F Davies1, G Morgan1 and B Barlogie1

As part of Total Therapy (TT) 3b, baseline marrow aspirates were subjected to two-color flow cytometry of nuclear DNA content and cytoplasmic immunoglobulin (DNA/CIG) as well as plasma cell gene expression profiling (GEP). DNA/CIG-derived parameters, GEP and standard clinical variables were examined for their effects on overall survival (OS) and progression-free survival (PFS). Among DNA/CIG parameters, the percentage of the light chain-restricted (LCR) cells and their cytoplasmic immunoglobulin index (CIg) were linked to poor outcome. In the absence of GEP data, low CIg < 2.8, albumin < 3.5 g/dl and age ≥ 65 years were significantly associated with inferior OS and PFS. When GEP information was included, low CIg survived the model along with GEP-defined high risk and low albumin. Low CIg was linked to beta-2-microglobulin > 5.5 mg/l, a percentage of LCR cells exceeding 50%, C-reactive protein > 8 mg/l and GEP-derived high centrosome index. Further analysis revealed an association of low CIg with 12 gene probes implicated in cell cycle regulation, differentiation and drug transportation from which a risk score was developed in TT3b that held prognostic significance also in TT3a, TT2 and HOVON trials, thus validating its general applicability. Low CIg is a powerful new prognostic variable and has identified potentially drug-able targets.

Leukemia (2015) 29, 1713–1720; doi:10.1038/leu.2015.65

INTRODUCTION
DNA flow cytometry detects aneuploidy in 70–80% of patients with multiple myeloma (MM).1 Hypo-diploidy has been associated with poor prognosis in patients treated with VAD (vincristine, doxorubicin and dexamethasone)2 that was overcome by the use of high-dose melphalan.3 In contrast, hyperdiploidy has been associated with more favorable outcomes.4,5 Here we have investigated, as part of Total Therapy 3b,6 the prognostic implications of two-color flow cytometry of nuclear DNA and cytoplasmic immunoglobulin (DNA/CIG) parameters in the context of all standard prognostic variables and plasma cell-based gene expression profiling (GEP).

PATIENTS AND METHODS
Treatment, staging and clinical endpoints
The details of the TT3b trial and clinical outcomes have been reported previously.6 Briefly, 177 eligible patients with newly diagnosed MM fulfilling CRAB criteria7 were enrolled, including 26 with one cycle of prior therapy. The protocol consisted of two induction cycles with VTD-PACE (bortezomib, thalidomide, dexamethasone and 4-day continuous infusions of cisplatin, doxorubicin, cyclophosphamide and etoposide) with hematopoietic progenitor cell collection upon recovery from the first cycle. Melphalan 200 mg/m2 was applied with each of the planned two transplants, with dose adjustments for age and renal function.8 Consolidation employed dose-reduced VTD-PACE for two cycles.

Maintenance with VRD (bortezomib, lenalidomide and dexamethasone) was planned for 3 years. In compliance with the institutional, federal and Helsinki declaration guidelines, all patients provided written informed consent before enrollment into the protocol that had been approved by the institutional review board.

All patients underwent a standardized staging workup. Bone marrow examinations included DNA/CIG, metaphase karyotyping to document the presence of cytogenetic abnormalities and GEP of purified plasma cells to assign molecular subclass,9 risk according to 70 (ref. 10) and 80 gene models,11 GEP-defined 1q21 amplification (amp1q21) as well as proliferation index12 and centrosome index.13 Clinical endpoints included the frequency of complete response13 and its duration counted from complete response onset to progression or death from any cause. Overall survival (OS) and progression-free survival (PFS) were measured from start of protocol therapy until progression or death from any cause for PFS and death from any cause for OS. Outcome data were updated as of 21 February 2014.

DNA/CIG assay
As part of the diagnostic workup, DNA/CIG was performed in all Total Therapy (TT) protocols with continuous updates on hardware and methodology. A modification introduced in August 2006 on the doublet discrimination method14 increased accuracy and reproducibility of results and has been uniformly applied with the start of TT3b enrollment. Details of the DNA/CIG method have been published.1 Briefly, bone marrow aspirates were separated by Hypaque-Ficoll (Sigma Aldrich, St Louis, MO, USA) gradient centrifugation, erythrocytes lysed with ammonium chloride and samples submitted to overnight ethanol fixation. Single-cell suspensions were exposed to anti-light chain reagents (Dako Kappa and Lambda

1Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA; 2Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR, USA and 3Cancer Research and Biostatistics, Seattle, WA, USA. Correspondence: Proffesor B Barlogie, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 West Markham St, Little Rock, AR 72205, USA.
E-mail: BarlogieBar@uams.edu
Received 24 November 2014; revised 12 February 2015; accepted 23 February 2015; accepted article preview online 10 March 2015; advance online publication, 27 March 2015
light chain (Agilent Technologies/Dako, Glostrup, Denmark) F(AB)2/FITC conjugated) and then counterstained for DNA with propidium iodide with the addition of RNase. Acquisition and analysis of the flow cytometric signals for the derived parameters were done through a BD FACScan Flow Cytometer (Beckton, Dickinson and Company, Franklin Lakes, NJ, USA) and the CellQuest/CellFit software (Beckton, Dickinson and Company). Routinely, a total of at least 10,000 events were recorded and analyzed. Assays with fewer than 500 events were rejected. To ensure maximum reproducibility of results, the same instrument was used for all measurements. The instrument was standardized daily with DNA Check Beads (Beckman Coulter, Inc., Brea, CA, USA) for consistent channel settings and coefficient of variation requirements of < 3%. A known positive patient specimen for each light chain was run daily and percent positive and light chain intensity were recorded. Titrated polyclonal F(AB)2 antibodies for light chains were used for low nonspecific binding, and excellent lot-to-lot reproducibility was documented. To quantitate the cellular DNA content, the DNA index (DI) was determined and calculated as the ratio of the mean of each light chain-positive G0/1 DNA peak divided by the mean of the light chain-negative diploid G0/1 peak on the x-axis. 

Acquisition of the G0/G1 populations was done through the modified doublet discrimination method and the CellQuest/CellFit software. A DI between 0.99 and 1.01 was referred to as diploid, whereas hyperdiploid implied DI > 1.01 and hypodiploid DI < 0.99. The excess of kappa- or lambda-positive cells identified the involved or light chain-restricted (LCR) cell population, the percentage of which was calculated in relation to the total number of gated events. Among the LCR cell population, discrete populations of cells with different nuclear DNA content were identified, which we refer to from here on as DNA stem lines, and their respective percentage could be calculated by referral to the total number of gated events. The involved DNA stem line with the highest percentage was considered dominant. The ploidy status was characterized from the DI of the dominant LCR DNA stem line. To quantitate the cytoplasmic immunoglobulin content of a light chain-positive population, the cytoplasmic immunoglobulin index (Cig) was used and calculated from the ratio of the geometric mean of the y-axis (cytoplasmic immunoglobulin fluorescence intensity) for the light chain-positive G0/1 peak divided by the y-axis geometric mean of the light chain-negative diploid G0/1 population. The Cig of each distinct DNA stem line was calculated as explained above. An example of a kappa-positive hyperdiploid MM with two distinct stem lines along with a case of high and a case of low Cig are shown in Supplementary Figures 1 and 2.

There was absolute concordance between the light chain classification of the LCR population by FDC and the conventional serological methods. In addition, the dominant Cig correlated with the ratio of M-protein to the percentage the dominant stem line (R2 = 0.621, P < 0.001). Although the DNA/Cig method described here does not discriminate between mature B cells and plasma cells, it does include all the myeloma cell subpopulations that have either an aberrant phenotype or a dim expression of the involved or light chain-restricted (LCR) cell population, the percentage of which was calculated in relation to the total number of gated events. Among the LCR cell population, discrete populations of cells with different nuclear DNA content were identified, which we refer to from here on as DNA stem lines, and their respective percentage could be calculated by referral to the total number of gated events. The involved DNA stem line with the highest percentage was considered dominant. The ploidy status was characterized from the DI of the dominant LCR DNA stem line. To quantitate the cytoplasmic immunoglobulin content of a light chain-positive population, the cytoplasmic immunoglobulin index (Cig) was used and calculated from the ratio of the geometric mean of the y-axis (cytoplasmic immunoglobulin fluorescence intensity) for the light chain-positive G0/1 peak divided by the y-axis geometric mean of the light chain-negative diploid G0/1 population. The Cig of each distinct DNA stem line was calculated as explained above. An example of a kappa-positive hyperdiploid MM with two distinct stem lines along with a case of high and a case of low Cig are shown in Supplementary Figures 1 and 2.

There was absolute concordance between the light chain classification of the LCR population by FDC and the conventional serological methods. In addition, the dominant Cig correlated with the ratio of M-protein to the percentage the dominant stem line (R2 = 0.621, P < 0.001). Although the DNA/Cig method described here does not discriminate between mature B cells and plasma cells, it does include all the myeloma cell subpopulations that have either an aberrant phenotype or a dim expression of the selected antigen or that even belong to the rare category of nonsecreting and nonproducing myeloma cells. When multiparameter flow cytometry was performed to identify LCR non-plasma B cells, their percentage was consistently found to be < 1%. 

Statistical Analysis

Kaplan–Meier methods were used to generate survival distribution graphs, and comparisons were made employing the log-rank test. The Pearson χ2 test was used for categorical comparisons, whereas Student’s t-test and Mann–Whitney U-test were used to compare the means or medians, respectively, of two different populations. Spearman’s rank correlation coefficient (Ri) was used as a measure of association between the ranks of two variables. For continuous variables, the running log-rank method was applied for the calculation of optimal cutoff points. Stepwise selection and Cox proportional hazard regression modeling were applied in multivariate analyses. The R2 statistic was used to evaluate the predictive power of different models. For the identification of differentially expressed gene probe sets between dichotomized groups, the Wilcoxon’s rank sum test of significance analysis of microarrays was used with an adjustment of a false discovery rate (FDR) of < 10% to be considered significant. The logarithmic base 2 expression levels of the gene probe sets were used in the analyses. Microarray data used in this study have been deposited in the NIH Gene Expression Omnibus under accession number GSE2658. A modified approach to the ComBat method was used to transform HOVON gene expression data to the same scale as TT3b while keeping the TT3b gene expression data fixed.

**RESULTS**

Standard baseline characteristics were available in 173 of 177 patients enrolled; in addition, 166 had GEP and 143 had DNA/Cig data. Herein we report on the 139 patients with complete data sets for both DNA/Cig and GEP analyses (Table 1). Standard variables and GEP data did not differ from the larger patient sets (data not shown) but, compared with earlier TT trials, cytogenetic abnormalities (42%) and GEP-70-defined high risk (23%) were more frequent. Aneuploidy was detected in 88%. DNA stem line frequencies were 1 in 18%, 2 in 70% and > 2 in 12%. In case of multiple LCR DNA stem lines, the designations of hyperdiploid applied to 58%, diploid to 38% and hypodiploid to 4%. There was

| Table 1. Patient baseline characteristics |
| Factor | n/N (%) |
| Age ≥ 65 years | 37/139 (27) |
| Male | 86/139 (62) |
| Caucasian | 130/139 (91) |
| IgG isotype | 75/139 (54) |
| IgA isotype | 33/139 (24) |
| Other | 31/139 (23) |
| Abnormal K/L ratio | 133/139 (96) |
| Involved light chain: K | 81/139 (61) |
| Involved light chain: L | 52/139 (39) |
| Albump < 3.5 g/dl | 67/139 (48) |
| B2M > 3.5 mg/l | 82/139 (60) |
| B2M > 5.5 mg/l | 43/139 (31) |
| ISS stage 1 | 35/139 (26) |
| ISS stage 2 | 59/139 (43) |
| ISS stage 3 | 43/139 (31) |
| Hb < 10 g/dl | 43/139 (31) |
| Creatinine ≥ 2 mg/dl | 9/139 (6) |
| CRP > 8 mg/l | 45/139 (32) |
| LDH > 190 U/l | 31/139 (22) |
| BMPC ≥ 33% | 93/134 (69) |
| Cytogetic abnormalities | 57/136 (42) |
| DNA/Cig parameters | |
| Aneuploid | 122/139 (88) |
| Dominant diploid | 53/139 (38) |
| Dominant hypodiploid | 81/139 (58) |
| Dominant hyperdiploid | 5/139 (4) |
| Number of DNA stem lines = 1 | 25/139 (18) |
| Number of DNA stem lines = 2 | 97/139 (70) |
| Number of DNA stem lines > 2 | 17/139 (12) |
| Any Cig < 2.8 | 60/139 (43) |
| Total LCR% > 50% | 28/139 (20) |

Abbreviations: B2M, beta-2-microglobulin; CD-1, cyclin D1; CD-2, cyclin D2; Cig, cytoplasmic immunoglobulin index; FDC, DNA and cytoplasmic flow cytometry; GEP, gene expression profile; Hb, hemoglobin; Ht, hyperdiploid; ISS, International Staging System; Lb, low bone; LCR%, light chain-restricted percentage; LDH, lactate dehydrogenase; MF, MAF/MAFB; PR, proliferation. n/N (%) denotes number with factor/number with valid data for factor.
absolute concordance between the light chain classification of the LCR population by FDC and the conventional serological methods. Moreover, there was a substantial correlation (R_s = 0.621, P < 0.0001) between the dominant Clg and the ratio of M-protein to the percentage of that stem line.

Clinical outcomes for the 139 patients of the TT3b study are shown in Supplementary Figure 3. In a univariate analysis, 4-year estimates were 73% for OS, 67% for PFS and 69% for complete response duration among the 67% achieving complete response. Other dehydrogenase response duration among the 67% achieving complete response. Estimates were 73% for OS, 67% for PFS and 69% for complete response duration among the 67% achieving complete response. In a univariate analysis, 4-year estimates were 73% for OS, 67% for PFS and 69% for complete response duration among the 67% achieving complete response.

Table 2. Cox proportional hazards regression modeling for OS and PFS

| Variable | n/N (%) | Overall survival | Progression-free survival |
|----------|---------|-----------------|--------------------------|
|          |         | HR (95% CI)     | P-value                  | HR (95% CI) | P-value |
| **Univariate** |         |                 |                          |             |         |
| Age ≥ 65 years | 37/139 (27) | 2.11 (1.20, 3.72) | 0.010 | 1.87 (1.12, 3.13) | 0.017 |
| Caucasian | 130/139 (94) | 0.47 (0.19, 1.20) | 0.115 | 0.40 (0.18, 0.89) | 0.025 |
| IgA Isotype | 33/139 (24) | 1.68 (0.93, 3.06) | 0.087 | 2.10 (1.25, 3.54) | 0.005 |
| Involved light chain: K | 81/133 (61) | 0.53 (0.30, 0.92) | 0.024 | 0.49 (0.30, 0.81) | 0.006 |
| Albumin < 3.5 g/dl | 67/139 (48) | 2.85 (1.57, 5.18) | < 0.001 | 2.11 (1.27, 3.52) | 0.004 |
| β2M > 5.5 mg/l | 43/137 (31) | 1.93 (1.09, 3.40) | 0.023 | 1.65 (0.99, 2.75) | 0.056 |
| Hb < 10 g/dl | 43/139 (31) | 2.07 (1.18, 3.62) | 0.011 | 1.85 (1.12, 3.06) | 0.016 |
| LDH > 190 U/l | 31/139 (22) | 2.17 (1.20, 3.95) | 0.011 | 1.89 (1.09, 3.27) | 0.023 |
| Cyto genetic abnormalities | 57/136 (42) | 2.07 (1.17, 3.65) | 0.012 | 1.80 (1.09, 2.96) | 0.021 |
| GEP70 high risk | 32/139 (23) | 4.86 (2.77, 8.53) | < 0.001 | 3.84 (2.31, 6.38) | < 0.001 |
| GEP80 high risk | 16/139 (12) | 6.72 (3.62, 12.47) | < 0.001 | 5.40 (2.99, 9.77) | < 0.001 |
| GEP PR subgroup | 24/139 (17) | 3.24 (1.80, 5.85) | < 0.001 | 3.26 (1.91, 5.55) | < 0.001 |
| GEP proliferation index ≥ 10 | 16/139 (12) | 4.49 (2.36, 8.52) | < 0.001 | 4.54 (2.48, 8.30) | < 0.001 |
| GEP centromere index ≥ 3 | 69/139 (50) | 2.75 (1.51, 4.98) | < 0.001 | 2.23 (1.39, 3.90) | 0.001 |
| 1q21 Amplification by GEP | 64/139 (46) | 1.83 (1.04, 3.22) | 0.035 | 2.38 (1.43, 3.97) | < 0.001 |
| Number of stem lines ≥ 2 | 17/139 (12) | 2.65 (1.35, 5.20) | 0.005 | 2.01 (1.04, 3.87) | 0.037 |
| Any Clg ≥ 2.8 | 28/139 (20) | 2.36 (1.35, 4.15) | 0.003 | 2.03 (1.24, 3.34) | 0.005 |
| Total LCR% ≥ 50 | 60/139 (43) | 2.43 (1.32, 4.47) | 0.004 | 1.88 (1.06, 3.32) | 0.030 |
| CIg 12-gene score < 5.35 | 24/139 (17) | 4.26 (2.35, 7.71) | < 0.001 | 3.34 (1.92, 5.82) | < 0.001 |

**Model 1**

| Variable | n/N (%) | Overall survival | Progression-free survival |
|----------|---------|-----------------|--------------------------|
| Age ≥ 65 years | 37/139 (27) | 2.34 (1.32, 4.16) | 0.004 | 1.96 (1.16, 3.31) | 0.011 |
| Albumin < 3.5 g/dL | 67/139 (48) | 3.02 (1.65, 5.51) | < 0.001 | 2.21 (1.32, 3.71) | 0.002 |
| Any Clg ≥ 2.8 | 60/139 (43) | 2.08 (1.18, 3.67) | 0.012 | 1.84 (1.11, 3.04) | 0.017 |

**Model 2**

| Variable | n/N (%) | Overall survival | Progression-free survival |
|----------|---------|-----------------|--------------------------|
| Age ≥ 65yr | 37/139 (26) | 1.86 (1.04, 3.33) | 0.036 | 1.58 (0.94, 2.68) | 0.086 |
| Albumin < 3.5 g/dl | 68/139 (49) | 2.49 (1.33, 4.65) | 0.004 | 1.88 (1.11, 3.19) | 0.019 |
| IgA Isotype | 34/139 (24) | 1.35 (0.74, 2.47) | 0.328 | 1.76 (1.04, 2.99) | 0.035 |
| GEP70 high risk | 32/139 (23) | 2.51 (1.23, 5.12) | 0.011 | 2.10 (1.09, 4.07) | 0.027 |
| GEP proliferation index ≥ 10 | 16/139 (12) | 2.19 (0.99, 4.83) | 0.052 | 2.40 (1.10, 5.24) | 0.027 |
| Any Clg ≥ 2.8 | 60/139 (43) | 2.02 (1.14, 3.58) | 0.016 | 1.87 (1.13, 3.09) | 0.015 |

**Model 3**

| Variable | n/N (%) | Overall survival | Progression-free survival |
|----------|---------|-----------------|--------------------------|
| Age ≥ 65 years | 37/139 (27) | 2.05 (1.14, 3.68) | 0.017 | 1.80 (1.06, 3.06) | 0.030 |
| Albumin < 3.5 g/dl | 67/139 (46) | 3.78 (2.04, 7.01) | < 0.001 | 2.68 (1.58, 4.55) | < 0.001 |
| CIg 12-gene score < 5.35 | 24/139 (17) | 4.56 (2.44, 8.54) | < 0.001 | 3.59 (2.09, 6.44) | < 0.001 |

Abbreviations: B2M, β2-microglobulin; Clg, cytoplasmic immunoglobulin index; CI, confidence interval; GEP, gene expression profile; HR, hazard ratio; HY, hyperdiploid; LDH, lactate dehydrogenase; PR, proliferation; LCR%, light chain-restricted percentage. P-value from Wald χ²-test in Cox Regression. NS2 multivariate results not statistically significant at 0.05 level. All univariate P-values reported with a P-value ≤ 0.1 are shown in bold. Multivariate model uses stepwise selection with entry level 0.1 and variable remains if meets the 0.05 level. A multivariate P-value > 0.05 indicates variable forced into model with significant variables chosen using stepwise selection. *Multivariate, CIg included and no GEP variables were allowed for selection. †Multivariate, all variables allowed for selection and no CI-derived gene probe variable included.  ‡Multivariate, GEP included and 12-gene score in place of any CIg.
prognostic factors in multiple myeloma
X Papanikolaou et al

Figure 1. Kaplan–Meier plots of OS and PFS in TT3b as defined by the multivariate survival analysis model (GEP variables excluded).

Table 3. Logistic regression analysis for factors associated with ‘any CIg < 2.8’

| Variable                          | N     | Any CIg < 2.8 | Any CIg > 2.8 | OR (95% CI)   | P-value |
|-----------------------------------|-------|---------------|---------------|---------------|---------|
| **Univariate**                    |       |               |               |               |         |
| B2M ≥ 3.5 mg/l                    | 137   | 44/82 (54%)   | 14/55 (25%)   | 3.39 (1.61, 7.15) | 0.0013  |
| B2M > 5.5 mg/l                    | 137   | 28/43 (65%)   | 30/94 (32%)   | 3.98 (1.86, 8.54) | 0.0004  |
| Hb < 10 g/dl                      | 139   | 27/43 (63%)   | 33/96 (34%)   | 3.22 (1.52, 6.81) | 0.0022  |
| CRP ≥ 8 mg/l                      | 139   | 27/45 (60%)   | 33/94 (35%)   | 2.77 (1.33, 5.76) | 0.0063  |
| LDH ≥ 190 U/l                     | 139   | 21/31 (68%)   | 39/108 (36%)  | 3.72 (1.59, 8.69) | 0.0025  |
| BMPC% > 33%                       | 134   | 49/93 (53%)   | 10/41 (24%)   | 3.45 (1.52, 7.85) | 0.0031  |
| Cytogenetic abnormalities         | 136   | 30/57 (53%)   | 28/79 (35%)   | 2.02 (1.01, 4.05) | 0.0468  |
| GEP70 high risk                   | 139   | 20/32 (63%)   | 40/107 (37%)  | 2.79 (1.23, 6.31) | 0.0136  |
| GEP80 high risk                   | 139   | 11/16 (69%)   | 49/123 (40%)  | 3.32 (1.09, 10.15) | 0.0352  |
| GEP MS subgroup                   | 139   | 4/20 (20%)    | 56/119 (47%)  | 0.28 (0.09, 0.89) | 0.0311  |
| GEP centrosome index ≥ 3          | 139   | 41/69 (59%)   | 19/70 (27%)   | 3.93 (1.93, 8.02) | 0.0002  |
| Number of stem lines > 2          | 139   | 11/17 (65%)   | 49/122 (40%)  | 2.73 (0.95, 7.87) | 0.0628  |
| Total LCR% > 50%                  | 139   | 21/28 (75%)   | 39/111 (35%)  | 5.54 (2.16, 14.18) | 0.0004  |
| **Multivariate**                  |       |               |               |               |         |
| B2M ≥ 5.5 mg/l                    | 132   | 28/42 (67%)   | 29/90 (32%)   | 3.04 (1.27, 7.25) | 0.0121  |
| CRP ≥ 8 mg/l                      | 132   | 25/40 (62%)   | 32/90 (36%)   | 3.35 (1.40, 8.01) | 0.0065  |
| GEP centrosome index ≥ 3          | 132   | 38/65 (58%)   | 19/67 (28%)   | 2.56 (1.12, 5.87) | 0.0263  |
| LCR% > 50%                        | 132   | 20/26 (77%)   | 37/106 (35%)  | 4.97 (1.68, 14.72) | 0.0038  |

Abbreviations: B2M, beta-2 microglobulin; BMPC%, bone marrow plasma cell percentage; CRP, C-reactive protein; CI, confidence interval; GEP, gene expression profile; Hb, hemoglobin; LDH, lactate dehydrogenase; MS, MMSET; LCR%, light chain-restricted percentage; OR, odds ratio. P-value from Wald χ²-test in logistic regression. NS2 multivariate results not statistically significant at 0.05 level. Univariate P-values reported if < 0.1. Multivariate model uses stepwise selection with entry level 0.1 and variable remains if meets the 0.05 level. A multivariate P-value > 0.05 indicates variable forced into model with significant variables chosen using stepwise selection.

standard parameters (beta-2-microglobulin, C-reactive protein, lactate dehydrogenase, hemoglobin, marrow plasmacytosis and cytogenetic abnormalities). Significant associations were also noted between low CIg and GEP-defined high risk (both GEP70 and GEP80), centrosome index and LCR%. The MS molecular subgroup was under-represented in patients with low CIg. High beta-2-microglobulin and C-reactive protein, centrosome index ≥ 3 and LCR exceeding 50% were independently and positively linked to low CIg in multivariate analysis.

As low CIg was strongly correlated with a multitude of different prognostic variables and retained independent adversity in the multivariate models 1 and 2 of Table 2, a comparative genomic analysis was carried out to identify gene probes distinguishing low from high CIg cases. Such analysis would enable us to validate our approach in trials where DNA/CIG had not been performed. The Wilcoxon’s rank sum test of significance analysis of microarrays of the GEP data for the two groups revealed 12 gene probe sets derived from 11 genes with a P-value < 10⁻⁴ and a false discovery rate < 10% (Table 4). A risk score (GEP12) was computed from the significant probe sets by subtracting the value of the expressions of the probes under-expressed in patients with low CIg from the sum of the expressions of the probes over-expressed in patients with low CIg from the sum of the expressions of the probes divided by the total number of probes. Using the running log-rank method, adverse prognostic implications were observed in TT3b for patients exhibiting a GEP12 score < 5.35. This GEP12 score < 5.35 substituted effectively for low CIg in model 3 of Table 2 and, importantly, dispelled GEP70 high risk and proliferation index. We next examined whether the GEP12 score held prognostic implications in other trials where the doublet discrimination method could not be retrospectively applied or DNA/CIG data were unavailable. Indeed, the GEP12 risk score segregated OS and PFS strongly in the bortezomib-containing TT3b training set (Figure 2a), in test sets of TT3a6 (Figure 2b) and in the HOVON65/GMMG-HD4 trials (Figure 2c). In TT2, PFS differed with a strong trend in OS, when both arms were considered combined (Figure 2d).

**DISCUSSION**

We show that the presence of low CIg as detected by DNA/CIG is a major adverse prognostic factor in TT3b, even when other GEP-derived prognostic factors were accounted for (Table 2). Although linked to a multitude of standard adverse prognostic factors...
The cells under endoplasmic reticulum stress that is dealt with by a high GEP-derived myeloma. Recently, the identification of a subpopulation of MM (Table 3) is characterized by a low proteasome capacity that puts the presence of GEP data. Factors that were not linked to CIg, such as older age and low albumin, retained independent adverse significance. The CI-linked GEP12 score outperformed GEP70-risk in TT2b (see Table 2) and was validated in TT3a, TT2 and HOVON trials. In this trial with contemporary treatment components, DNA/CIG ploidy status (DI) per se was not prognostic for either OS or PFS, even when an optimal cutoff point approach for the DI value was obtained (data not shown). We believe that this reflects the improvement in prognosis through newer treatments.

The clinical significance of CIg in MM may be related to its impact on the pathophysiologic of the plasma cell. Immunoglobulin-producing and -secreting cells, normal or malignant, are characterized by a low proteasome capacity that puts the cells under endoplasmic reticulum stress that is dealt with by the unfolded protein response. Failure of the plasma cell to mount an effective unfolded protein response in the presence of the immunoglobulin production stress leads to apoptosis.

Bortezomib targets the proteasome and increases endoplasmic reticulum stress. Consequently, in cases of high CIg signifying high immunoglobulin production, endoplasmic reticulum stress is augmented further by exposure to bortezomib, resulting in accelerated apoptosis regardless of other biologic characteristics of that cell. This hypothesis is supported by the finding that the CIg-derived gene score was significant in the bortezomib-containing TT3a/b and HOVON studies but to a lesser extent in TT2 devoid of a proteasome inhibiting agent. The GEP-defined MS molecular subgroup, corresponding to the t(4; 14) translocation and known to benefit from bortezomib, was associated with a high CIg in our series (Table 3), thus providing a potential explanation for the sensitivity of this subgroup to proteasome inhibitors.

Low CIg was associated with aggressive disease characteristics (Table 3). Recently, the identification of a subpopulation of MM cells with a reduction in the immunoglobulin production, pre-plasmablastic morphology and immaturity when examined by multicolor flow cytometry has been linked with proteasome inhibition resistance and reduced PFS. The linkage of low CIg to a high GEP-defined centrosome index is novel. Beyond providing support for the successful completion of the anaphase in eukaryotic cells, centrosomes also serve in the orientation of the cellular cilia and are hence an integral part of a successful cellular migration, perhaps facilitating the generation of extra-metullary disease. Interestingly, a centrosome inhibitor has shown promising activity in preclinical models of MM, thus potentially providing a valuable drug for patients with low CIg myeloma.

(215422_at) ACSM1 encodes for a protein with a mitochondrial location that is implicated in the metabolism of fatty acids, and (239844_x_at) ACSM1 encodes for a protein that recently has been shown to be involved in cell cycle regulation and promote apoptosis in solid tumors, whereas (226286_at) ELMOD encodes for a cytoskeleton protein that recently has been shown to be involved in cell cycle regulation and promote apoptosis in solid tumors, and hitherto unsuspected MM-relevant genes. These genes, when used in a GEP12 risk score, proved to be prognostically powerful in the multivariate models even in the presence of GEP data. Factors that were not linked to CIg, such as older age and low albumin, retained independent adverse significance. The CI-linked GEP12 score outperformed GEP70-risk in TT3b (see Table 2) and was validated in TT3a, TT2 and HOVON trials. In this trial with contemporary treatment components, DNA/CIG ploidy status (DI) per se was not prognostic for either OS or PFS, even when an optimal cutoff point approach for the DI value was obtained (data not shown). We believe that this reflects the improvement in prognosis through newer treatments.

The clinical significance of CIg in MM may be related to its impact on the pathophysiologic of the plasma cell. Immunoglobulin-producing and -secreting cells, normal or malignant, are characterized by a low proteasome capacity that puts the cells under endoplasmic reticulum stress that is dealt with by the unfolded protein response. Failure of the plasma cell to mount an effective unfolded protein response in the presence of the immunoglobulin production stress leads to apoptosis.

Bortezomib targets the proteasome and increases endoplasmic reticulum stress. Consequently, in cases of high CIg signifying high immunoglobulin production, endoplasmic reticulum stress is augmented further by exposure to bortezomib, resulting in accelerated apoptosis regardless of other biologic characteristics of that cell. This hypothesis is supported by the finding that the CIg-derived gene score was significant in the bortezomib-containing TT3a/b and HOVON studies but to a lesser extent in TT2 devoid of a proteasome inhibiting agent. The GEP-defined MS molecular subgroup, corresponding to the t(4; 14) translocation and known to benefit from bortezomib, was associated with a high CIg in our series (Table 3), thus providing a potential explanation for the sensitivity of this subgroup to proteasome inhibitors.

Low CIg was associated with aggressive disease characteristics (Table 3). Recently, the identification of a subpopulation of MM cells with a reduction in the immunoglobulin production, pre-plasmablastic morphology and immaturity when examined by multicolor flow cytometry has been linked with proteasome inhibition resistance and reduced PFS. The linkage of low CIg to a high GEP-defined centrosome index is novel. Beyond providing support for the successful completion of the anaphase in eukaryotic cells, centrosomes also serve in the orientation of the cellular cilia and are hence an integral part of a successful cellular migration, perhaps facilitating the generation of extra-metullary disease. Interestingly, a centrosome inhibitor has shown promising activity in preclinical models of MM, thus potentially providing a valuable drug for patients with low CIg myeloma.

Table 4. List of differentially expressed gene probes with a q-value less than 0.1 from the Wilcoxon rank sum test significance analysis of microarrays of the ‘any CIg < 2.8’ and ‘all CIg ≥ 2.8’ groups of patients.

| Affymetrix probe | Symbol | Chromosome | Description | Mean signal: any CIg < 2.8 | Mean signal: any CIg ≥ 2.8 | P-value | q-value |
|-----------------|--------|------------|-------------|---------------------------|---------------------------|---------|--------|
| 239844_s_at     | C1orf228 | chr1p34.1  | Chromosome 1 open reading frame 228 | 6.581345 | 7.389482 | 1.49E-06 | 0.019418 |
| 213187_x_at     | FTL    | chr19q13.33 | Ferritin, light polypeptide | 14.14725 | 14.52846 | 1.65E-06 | 0.019418 |
| 215422_at       | ACSM1  | chr16p12.3  | Acyl-CoA synthetase medium-chain family member 1 | 4.267809 | 5.102353 | 1.65E-06 | 0.019418 |
| 228268_at       | ELMOD3 | chr2p11.12  | ELMO/CEO-12 domain containing 3 | 8.116286 | 8.691678 | 1.78E-06 | 0.019418 |
| 209776_s_at     | SLC19A1 | chr21q22.3  | Solute carrier family 19 (folute transporter), member 1 | 6.504965 | 5.352083 | 1.11E-05 | 0.08482 |
| 217622_at       | RHBD3  | chr19q13.33 | Ferritin, light polypeptide | 8.329782 | 8.782621 | 1.16E-05 | 0.08482 |
| 212788_x_at     | FTL    | chr19q13.33 | Ferritin, light polypeptide | 14.7247 | 15.07511 | 1.37E-05 | 0.085441 |
| 227896_at       | BCCIP  | chr10q26.1  | BCC1 and CDKN1A interacting protein | 8.344684 | 7.80806 | 1.68E-05 | 0.091845 |
| 215940_x_at     | IGHM   | chr14q23.33 | Immunoglobulin heavy constant mu | 9.263938 | 11.03899 | 2.01E-05 | 0.09394 |
| 219117_s_at     | FKBP11 | chr12q13.12 | FK506 binding protein 11, 19 kDa | 14.69862 | 15.04902 | 2.30E-05 | 0.09394 |
| 207408_at       | SLC22A14 | chr3p21.3  | Solute carrier family 22, member 14 | 8.967901 | 9.309341 | 2.46E-05 | 0.09394 |
| 204251_s_at     | CEPI64 | chr11q23.3  | Centrosomal protein 164kDa | 8.27905 | 7.790321 | 2.58E-05 | 0.09394 |

Abbreviation: CIg, cytoplasmic immunoglobulin index. With gray background are portrayed the gene probes that are upregulated in the ‘any CIg < 2.8’ group.
Figure 2. Kaplan–Meier plots of OS and PFS in TT3b (a), TT3a (b), ComBat-transformed HOVON (c) and TT2 (d), according to the 12-probeset score for genes associated with CIg.
a multitude of MM trials and may provide useful information for the evaluation and establishment of new targeted therapies.

**CONFLICT OF INTEREST**

BB received research funding from Celgene Corp. and Millennium Pharmaceuticals, Inc. and is a consultant for Celgene Corp., Millennium Pharmaceuticals, Inc., Onyx Pharmaceuticals, Inc., and Amgen, Inc. He is a co-inventor on patents and patent applications related to use of gene expression profiling in cancer medicine that have been licensed to Myeloma Health, LLC, but has no financial interests in this company. The remaining authors declare no conflict of interest.

**ACKNOWLEDGEMENTS**

We thank the patients and staff of the Myeloma Institute for Research and Therapy. This work was supported in part by PO1 CA 55819 from the National Cancer Institute.

**AUTHOR CONTRIBUTIONS**

Conception and design: BB and XP. Administrative support: BB and JE. Provision of study material or patients: BB, RO, XP, CH, SW, FvR, ET, DA, AJ, M2, RK and YJ. Collection and assembly of data: RO, XP and CB. Data analysis and interpretation: XP, AR, CS, SY, JE and BB. Manuscript writing: All authors. Final approval of manuscript: All authors.

**REFERENCES**

1. Barlogie B, Alexanian R, Pershouse M, Smallwood L, Smith L. Cytoplasmic immunoglobulin content in multiple myeloma. J Clin Invest 1985; 76: 765–769.
2. Barlogie B, Alexanian R, Dixon D, Smith L, Smallwood L, Delasalle K. Prognostic implications of tumor cell DNA and RNA content in multiple myeloma. Blood 1985; 66: 338–341.
3. Greipp PR, Trendle MC, Leong T, Oken MM, Kay NE, Van Ness B et al. Is flow cytometric DNA content hypodiploidy prognostic in multiple myeloma? Leuk Lymphoma 1999; 35: 83–89.
4. Garcia-Sanz R, Orfao A, Gonzalez M, Moro MJ, Hernandez JM, Ortega F et al. Prognostic implications of DNA aneuploidy in 156 untreated multiple myeloma patients. Castelano-Leones (Spain) Cooperative Group for the Study of Monoclonal Gammopathies. Br J Haematol 1995; 90: 106–112.
5. Chng WJ, Santana-Davila R, Van Wier SA, Ahmann GJ, Jalal SM, Bergsagel PL et al. Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and light translocations. Leukemia 2006; 20: 807–813.
6. Nair B, van Rhee F, Shaughnessy Jr JD, Anaissie E, Szymonifka J, Hoering A et al. Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance. Blood 2010; 115: 4168–4173.
7. International Myeloma Working G. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003; 121: 749–757.
8. Barlogie B, Anaissie E, van Rhee F, Pineda-Roman M, Zangari M, Shaughnessy J et al. The Arkansas approach to therapy of patients with multiple myeloma. Best Pract Res Clin Haematol 2007; 20: 761–781.
9. Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S et al. The molecular classification of multiple myeloma. Blood 2006; 108: 2020–2028.
10. Shaughnessy Jr JD, Zhan F, Burginton BE, Huang Y, Colla S, Hanamura I et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007; 109: 2276–2284.
11. Shaughnessy Jr JD, Qiu P, Usmani S, Heuck CJ, Zhang Q, Zhou Y et al. Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3. Blood 2011; 118: 3521–3524.
12. Chng WJ, Ahmann GJ, Henderson K, Santana-Davila R, Greipp PR, Gertz MA et al. Clinical implications of centrosome amplification in plasma cell neoplasm. Blood 2006; 107: 3649–3655.
13. Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467–1473.
14. Westrop RP, Chrest FJ, Leary JP, Morris C, Stebler-Stevenson MA, Gabrielson E. Doubledet discrimination in DNA cell-cycle analysis. Cytometry 2001; 46: 296–306.
macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals. Leukemia 2007; 21: 541–549.

43 Frigyesi I, Adolfsson J, Ali M, Kronborg Christophersen M, Johnsson E, Turesson I et al. Robust isolation of malignant plasma cells in multiple myeloma. Blood 2014; 123: 1336–1340.

44 Nishiwaki T, Daigo Y, Tamari M, Fujii Y, Nakamura Y. Molecular cloning, mapping, and characterization of two novel human genes, ORCTL3 and ORCTL4, bearing homology to organic-cation transporters. Cytogenet Cell Genet 1998; 83: 251–255.

45 Bahar A, Whitby P, Holley S, Hoban PR, Elder JB, Deakin M et al. Primary colorectal tumors fail to express the proapoptotic mediator PTAG and its reexpression augments drug-induced apoptosis. Genes Chromosomes Cancer 2007; 46: 202–212.

46 Johnson KR, Longo-Guess CM, Gagnon LH. Mutations of the mouse ELMO domain containing 1 gene (Elmo1) link small GTPase signaling to actin cytoskeleton dynamics in hair cell stereocilia. PloS One 2012; 7: e36074.

47 Iwai N, Mannami T, Tominoue H, Ono K, Iwanaga Y. An acyl-CoA synthetase gene family in chromosome 16p12 may contribute to multiple risk factors. Hypertension 2003; 41: 1041–1046.

48 Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G et al. The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res 2004; 14: 2121–2127.

Supplementary Information accompanies this paper on the Leukemia website (http://www.nature.com/leu)